458 related articles for article (PubMed ID: 20826181)
1. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.
Kehne JH; Cain CK
Pharmacol Ther; 2010 Dec; 128(3):460-87. PubMed ID: 20826181
[TBL] [Abstract][Full Text] [Related]
2. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.
Kehne JH
CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):163-82. PubMed ID: 17511614
[TBL] [Abstract][Full Text] [Related]
3. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
Kehne J; De Lombaert S
Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):467-93. PubMed ID: 12769601
[TBL] [Abstract][Full Text] [Related]
4. Don't stress about CRF: assessing the translational failures of CRF
Spierling SR; Zorrilla EP
Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
[TBL] [Abstract][Full Text] [Related]
5. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
Valdez GR
CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.
Hauger RL; Risbrough V; Brauns O; Dautzenberg FM
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):453-79. PubMed ID: 16918397
[TBL] [Abstract][Full Text] [Related]
7. The role of corticotropin-releasing factor in depression and anxiety disorders.
Arborelius L; Owens MJ; Plotsky PM; Nemeroff CB
J Endocrinol; 1999 Jan; 160(1):1-12. PubMed ID: 9854171
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
Holmes A; Heilig M; Rupniak NM; Steckler T; Griebel G
Trends Pharmacol Sci; 2003 Nov; 24(11):580-8. PubMed ID: 14607081
[TBL] [Abstract][Full Text] [Related]
10. Chronic stress-induced alterations in amygdala responsiveness and behavior--modulation by trait anxiety and corticotropin-releasing factor systems.
Sandi C; Cordero MI; Ugolini A; Varea E; Caberlotto L; Large CH
Eur J Neurosci; 2008 Nov; 28(9):1836-48. PubMed ID: 18973598
[TBL] [Abstract][Full Text] [Related]
11. Progress in corticotropin-releasing factor-1 antagonist development.
Zorrilla EP; Koob GF
Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
[TBL] [Abstract][Full Text] [Related]
12. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.
Hauger RL; Risbrough V; Oakley RH; Olivares-Reyes JA; Dautzenberg FM
Ann N Y Acad Sci; 2009 Oct; 1179():120-43. PubMed ID: 19906236
[TBL] [Abstract][Full Text] [Related]
13. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
Taché Y; Martinez V; Million M; Maillot C
Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
[TBL] [Abstract][Full Text] [Related]
14. CRF1 receptors as a therapeutic target for irritable bowel syndrome.
Martinez V; Taché Y
Curr Pharm Des; 2006; 12(31):4071-88. PubMed ID: 17100612
[TBL] [Abstract][Full Text] [Related]
15. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
Fahmy H; Kuppast B; Ismail MT
Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
[TBL] [Abstract][Full Text] [Related]
16. CRF receptors as a potential target in the development of novel pharmacotherapies for depression.
Valdez GR
Curr Pharm Des; 2009; 15(14):1587-94. PubMed ID: 19442175
[TBL] [Abstract][Full Text] [Related]
17. Corticotropin-releasing factor 1 receptor antagonists: a patent review.
Williams JP
Expert Opin Ther Pat; 2013 Aug; 23(8):1057-68. PubMed ID: 23642023
[TBL] [Abstract][Full Text] [Related]
18. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.
Ising M; Zimmermann US; Künzel HE; Uhr M; Foster AC; Learned-Coughlin SM; Holsboer F; Grigoriadis DE
Neuropsychopharmacology; 2007 Sep; 32(9):1941-9. PubMed ID: 17287823
[TBL] [Abstract][Full Text] [Related]
19. The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury.
Kosari-Nasab M; Sadeghi T; Bashiri H; Shokouhi G; Salari AA
Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):220-228. PubMed ID: 30883392
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin releasing factor receptor antagonists for major depressive disorder.
Paez-Pereda M; Hausch F; Holsboer F
Expert Opin Investig Drugs; 2011 Apr; 20(4):519-35. PubMed ID: 21395482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
